Equillium Inc
NASDAQ:EQ
Equillium Inc
Effect of Foreign Exchange Rates
Equillium Inc
Effect of Foreign Exchange Rates Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Effect of Foreign Exchange Rates | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Effect of Foreign Exchange Rates
$32k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Effect of Foreign Exchange Rates
-$65m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Effect of Foreign Exchange Rates
-$40m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-82%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Effect of Foreign Exchange Rates
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Effect of Foreign Exchange Rates
-$42.6m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Effect of Foreign Exchange Rates
-$700k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
32k
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Effect of Foreign Exchange Rates amounts to 32k USD.
You don't have any saved screeners yet